Eli Lilly notches another positive baricitinib eczema trial, but has Dermira made it obsolete?
Entering today, most of what you needed to know about Eli Lilly’s JAK inhibitor baricitinib could be found in two places:
In the FDA-mandated, 1,000-plus word, bolded note now appended to the end of every press release about the drug that begins: “WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS.”
And in the run-up to the JP Morgan Healthcare Conference, when Eli Lilly dropped $1.1 billion on the anti-inflammatory skin biotech Dermira – a move that SVB Leerink’s Pasha Sarraf had predicted a month prior based on the consistently meh results baricitinib had produced in Phase III trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.